Association of N-acetylaspartate and cerebrospinal fluid Aβ42 in dementia

Journal of Alzheimer's Disease

Volumn 27, Issue 2, 2011, Pages 393-399

  Jessen, Frank ^a,b   Lewczuk, Piotr ^c   Gür, Okan ^a   Block, Wolfgang ^a   Ende, Gabriele ^d   Frölich, Lutz ^d   Hammen, Thilo ^c   Arlt, Sönke ^e   Kornhuber, Johannes ^c   Kucinski, Thomas ^f   Popp, Julius ^g   Peters, Oliver ^h   Maier, Wolfgang ^a,b   Träber, Frank ^a   Wiltfang, Jens ⁱ  

^a UNIVERSITY OF BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Alzheimer's disease; medial temporal lobe; mitochondria; N acetylaspartate; proton MR spectrocopy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; N ACETYLASPARTIC ACID; TAU PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL LOBE;

EID: 81855190670     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110398     Document Type: Article

References (50)

1. Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58, 495-505. (Pubitemid 41377212)
2. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease, FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32, 486-510. (Pubitemid 40591181)
3. Swerdlow RH, Khan SM (2009) The Alzheimer's disease mitochondrial cascade hypothesis: An update. Exp Neurol 218, 308-315.
4. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80, 91-100. (Pubitemid 34614581)
5. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452. (Pubitemid 38495942)
6. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25, 672-679.
7. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. J Neurosci 25, 10874-10883. (Pubitemid 41692617)
8. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: From neurodiag-nostics to neurobiology. Prog Neurobiol 81, 89-131.
9. Pan JW, Takahashi K (2005) Interdependence of N-acetyl aspartate and high-energy phosphates in healthy human brain. Ann Neurol 57, 92-97. (Pubitemid 40053319)
10. Stork C, Renshaw PF (2005) Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spec-troscopy research. Mol Psychiatry 10, 900-919. (Pubitemid 41486483)
11. Benarroch EE (2008) N-acetylaspartate and N-acetylas-partylglutamate: Neurobiology and clinical significance. Neurology 70, 1353-1357. (Pubitemid 351550340)
12. Kantarci K (2007) 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80, 146-152.
13. Klunk WE, Panchalingam K, Moossy J, McClure RJ, Pet-tegrew JW (1992) N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: A preliminary proton nuclear magnetic resonance study. Neurology 42, 1578-1585.
14. Mohanakrishnan P, Fowler AH, Vonsattel JP, Husain MM, Jolles PR, Liem P, Komoroski RA (1995) An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res 102, 503-510.
15. Passani LA, Vonsattel JP, Carter RE, Coyle JT (1997) N- acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol Chem Neuropathol 31, 97-118.
16. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR, Jr (2008) Alzheimer disease: Post-mortem neu-ropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248, 210-220.
17. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Alzheimer's Disease Neuroimag-ing Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
18. Engelborghs S, De Vreese K, Van de Casteele T, Vander-stichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159. (Pubitemid 351822410)
19. Lewczuk P, Wiltfang J (2008) Neurochemical dementia diagnostics: State of the art and research perspectives. Proteomics 8, 1292-1301. (Pubitemid 351462934)
20. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
21. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519. (Pubitemid 43358072)
22. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A (2009) Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927-934.
23. Kornhuber J, Schmidtke K, Frolich L, Perneczky R, Wolf S, Hampel H, Jessen F, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Pantel J, Rien-hoff O, Seuchter SA, Rüther E, Henn F, Maier W, Wiltfang J (2009) Early and differential diagnosis of dementia and mild cognitive impairment: Design and cohort baseline character-isticsofthe German Dementia Competence Network Dement. Geriatr Cogn Disord 27, 404-417.
24. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erk-injuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246. (Pubitemid 39222993)
25. Lewczuk P, Kornhuber J, Wiltfang J (2006) The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm 113, 1075-1080. (Pubitemid 44079939)
26. Träber F, Block W, Freymann N, Gür O, Kucinski T, Hammen T, Ende G, Pilatus U, Hampel H, Schild HH, Heun R, Jessen F (2006) A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. Eur Radiol 16, 1096-1103.
27. Jessen F, Gür O, Block W, Ende G, Frölich L, Hammen T, Wiltfang J, Kucinski T, Jahn H, Heun R, Maier W, Kölsch H, Kornhuber J, Träber F (2009) A multicenter (1) H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72, 1735-1740.
28. Vanhamme L, van den Boogaart A, van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129, 35-43. (Pubitemid 127454051)
29. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Essel-mann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: A mul-ticenter study. Mol Psychiatry 15, 138-145.
30. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiol Aging 29, 812-818. (Pubitemid 351601894)
31. Jessen F, Block W, Träber F, Keller E, Flacke S, Lamerichs R, Schild HH, Heun R (2001) Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 57, 930-932. (Pubitemid 32845528)
32. Zimmerman ME, Pan JW, Hetherington HP, Katz MJ, Vergh-ese J, Buschke H, Derby CA, Lipton RB (2008) Hippocampal neurochemistry, neuromorphometry, and verbal memory in nondemented older adults. Neurology 70, 1594-1600. (Pubitemid 351620314)
33. Haga KK, Khor YP, Farrall A, Wardlaw JM (2009) A systematic review of brain metabolite changes, measured with (1) H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging 30, 353-363.
34. Reddy PH (2009) Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218, 286-292.
35. Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL, Petersen KF (2009) Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 30, 211-221.
36. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996) Inhibition of N-acetylaspartate production: Implications for 1H MRS studies in vivo. Neuroreport 7, 1397-1400. (Pubitemid 26281000)
37. Manczak M, Park BS, Jung Y, Reddy PH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: Implications for early mitochon-drialdysfunction and oxidative damage. Neuromolecular Med 5, 147-162. (Pubitemid 38596548)
38. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brin-ton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathologyinfemale mousemodelofAlzheimer's disease. Proc Natl Acad Sci USA 106, 14670-14675.
39. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Dröse S, Brandt U, Savaskan E, Czech C, Götz J, Eckert A (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 106, 20057-20062.
40. Wang X, Su B, Perry G, Smith MA, Zhu X (2007) Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med 43, 1569-1573. (Pubitemid 350122990)
41. Hauptmann S, Scherping I, Dröse S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Müller WE (2009) Mito-chondrial dysfunction: Anearly event inAlzheimer pathology accumulates with ageinADtransgenic mice. Neurobiol Aging 30, 1574-1576.
42. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160, 2003-2011. (Pubitemid 39619638)
43. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W (2006) Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67, 528-530. (Pubitemid 44214992)
44. Vukovich R, Perneczky R, Drzezga A, Förstl H, Kurz A, Riemenschneider M (2009) Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease. Dement Geriatr Cogn Disord 27, 474-480.
45. Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Itoh M, Iwatsubo T, Tomita T, Sasaki H (1999) Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci Lett 273, 203-207. (Pubitemid 29430185)
46. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
47. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anan-datheerthavarada HK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brainisassociated withmitochon-drial dysfunction. J Neurosci 26, 9057-9068. (Pubitemid 44319397)
48. Herukka SK, Pennanen C, Soininen H, Pirttilä T (2008) CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis 14, 51-57. (Pubitemid 352039012)
49. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta (42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65, 176-183.
50. Rhein V, Eckert A (2007) Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function-role of glucose metabolism and insulin signalling. Arch Hysiol Biochem 113, 131-141. (Pubitemid 47547386)